Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building a knockoff drug powerhouse and has become one of the world’s most successful female ...

Biocon Biologics has received USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog Insulin Aspart for diabetes treatment. Intended to improve glycemic control in individuals with ...

Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "We are very pleased to have achieved the negligible-risk rating from Morningstar Sustainalytics.

AGC Biologics, your friendly CDMO expert, today announced a new service agreement with Okayama University, a prominent national university in Japan. This project will leverage AGC Biologics ...

Biocon Biologics is a global leader in biosimilars and insulin production and is among the top three global players for rh- Insulin and Insulin Glargine, providing over 9.2 billion doses of insulin ...

Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors July 15, 2025 — 05:50 pm EDT Written by Zacks Equity Research for Zacks -> ...

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States ...

The global biotechnology market size is projected to surpass USD 5.71 trillion by 2034, driven by breakthroughs in biologics, tissue engineering, regenerative therapies, and chromatography. With a ...

The widespread use of radiofrequency (RF) communication has increased the exposure of organisms to electromagnetic fields, sparking a debate over the potential health effects of weak RF ...

Mennonites in Belize own thousands of hectares of rainforest that make up part of a “biological corridor” for wildlife moving between numerous protected areas. The Mennonites started clearing ...

Objectives Infliximab, an anti-TNF agent, is used to treat sarcoidosis that does not respond to corticosteroids or second-line agents. The efficacy of other anti-TNF agents, non-TNF biologics and ...